Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 501–600 of 15,747
Sandmann, F. G., Davies, N. G., Vassall, A., Edmunds, W. J., Jit, M., Sun, F. Y., Villabona-Arenas, C. J., Nightingale, E. S., Showering, A., Knight, G. M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00079-7 · Cited by 176
In vivo editing of lung stem cells for durable gene correction in mice
Sun, Y., Chatterjee, S., Lian, X., Traylor, Z., Sattiraju, S. R., Xiao, Y., Dilliard, S. A., Sung, Y.-C., Kim, M., Lee, S. M., et al. (2024) · Science · doi:10.1126/science.adk9428 · Cited by 183
Clinical and immunological effects of mRNA vaccines in malignant diseases
Heine, A., Juranek, S., & Brossart, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01339-1 · Cited by 181
Ocular Adverse Events After COVID-19 Vaccination
Ng, X. L., Betzler, B. K., Testi, I., Ho, S. L., Tien, M., Ngo, W. K., Zierhut, M., Chee, S. P., Gupta, V., Pavesio, C. E., et al. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1976221 · Cited by 181
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
(2022) · doi:10.1016/j.cell.2022.01.027 · Cited by 179
“…vaccine efficacy in different demographic groups that could be suggestive of largely comparable immune responses to the vaccine (Baden et al., 2020; Polack et al., 2020), a direct comparison of GC responses 1020 Cell 185, 1008–1024, March 17, 2022 between demographic groups has not been performed.”
Human IgG and IgA responses to COVID-19 mRNA vaccines
Wisnewski, A. V., Campillo Luna, J., & Redlich, C. A. (2021) · PLOS ONE · doi:10.1371/journal.pone.0249499 · Cited by 179
Drug combination therapy for emerging viral diseases
Shyr, Z. A., Cheng, Y.-S., Lo, D. C., & Zheng, W. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.008 · Cited by 182
“At the time of writing, three COVID-19 vaccines, including two mRNA vaccines (Moderna’s mRNA-1273 and Pfizer’s BNT162b2) 63–65 and the single-dose Janssen vaccine, have been granted Emergency Use Authorization (EUA) by the FDA and other regulatory agencies.”
Loganathan, T., & Doss C, G. P. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-022-00947-4 · Cited by 181
Nguyen, V. H., Thuy, V. N., Van, T. V., Dao, A. H., & Lee, B.-J. (2022) · OpenNano · doi:10.1016/j.onano.2022.100064 · Cited by 180
Aldén, M., Olofsson Falla, F., Yang, D., Barghouth, M., Luan, C., Rasmussen, M., & De Marinis, Y. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44030073 · Cited by 179
“Specifically, COVID-19 mRNA vaccine BNT162b2 developed by Pfizer and BioNTech has been evaluated in successful clinical trials [2–4] and administered in national COVID-19 vaccination campaigns in different regions around the world [5–8].”
Klein, N. P., Stockwell, M. S., Demarco, M., Gaglani, M., Kharbanda, A. B., Irving, S. A., Rao, S., Grannis, S. J., Dascomb, K., Murthy, K., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7109e3 · Cited by 179
Braun-Moscovici, Y., Kaplan, M., Braun, M., Markovits, D., Giryes, S., Toledano, K., Tavor, Y., Dolnikov, K., & Balbir-Gurman, A. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220503 · Cited by 178
Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines
Swetha, K., Kotla, N. G., Tunki, L., Jayaraj, A., Bhargava, S. K., Hu, H., Bonam, S. R., & Kurapati, R. (2023) · Vaccines · doi:10.3390/vaccines11030658 · Cited by 179
“Clinical development of other LNP-based RNA therapeutics, especially mRNA vaccines (including two recent breakthrough LNP-based mRNA vaccines, mRNA-1273 (Moderna), and BNT162b2 (BioNTech) for COVID-19), has been greatly accelerated in response to the success of MC3 (ionizable lipid used for Onpattro® product by Alnyla…”
BackgroundKuzmina, A., Khalaila, Y., Voloshin, O., Keren-Naus, A., Boehm-Cohen, L., Raviv, Y., Shemer-Avni, Y., Rosenberg, E., & Taube, R. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.008 · Cited by 179
Siegel, C. A., Melmed, G. Y., McGovern, D. P., Rai, V., Krammer, F., Rubin, D. T., Abreu, M. T., & Dubinsky, M. C. (2021) · Gut · doi:10.1136/gutjnl-2020-324000 · Cited by 179
Delivery Strategies for mRNA Vaccines
Ramachandran, S., Satapathy, S. R., & Dutta, T. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-021-00417-5 · Cited by 177
Whitley, J., Zwolinski, C., Denis, C., Maughan, M., Hayles, L., Clarke, D., Snare, M., Liao, H., Chiou, S., Marmura, T., et al. (2022) · Translational Research · doi:10.1016/j.trsl.2021.11.009 · Cited by 176
Triggle, C. R., Bansal, D., Ding, H., Islam, M. M., Farag, E. A. B. A., Hadi, H. A., & Sultan, A. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631139 · Cited by 177
Nanovaccines: A game changing approach in the fight against infectious diseases
Priyanka, Abusalah, M. A. H., Chopra, H., Sharma, A., Mustafa, S. A., Choudhary, O. P., Sharma, M., Dhawan, M., Khosla, R., Loshali, A., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115597 · Cited by 179
Nucleic acid drugs: recent progress and future perspectives
Sun, X., Setrerrahmane, S., Li, C., Hu, J., & Xu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02035-4 · Cited by 179
In vivo kinetics of SARS-CoV-2 infection and its relationship with a person’s infectiousness
Ke, R., Zitzmann, C., Ho, D. D., Ribeiro, R. M., & Perelson, A. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111477118 · Cited by 173
Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization
(2021) · doi:10.1101/2021.03.01.433466 · Cited by 626
The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
Chodick, G., Tene, L., Rotem, R. S., Patalon, T., Gazit, S., Ben-Tov, A., Weil, C., Goldshtein, I., Twig, G., Cohen, D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab438 · Cited by 176
Di Gennaro, F., Murri, R., Segala, F. V., Cerruti, L., Abdulle, A., Saracino, A., Bavaro, D. F., & Fantoni, M. (2021) · Viruses · doi:10.3390/v13030371 · Cited by 175
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
Hagin, D., Freund, T., Navon, M., Halperin, T., Adir, D., Marom, R., Levi, I., Benor, S., Alcalay, Y., & Freund, N. T. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.05.029 · Cited by 174
Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination
Suberi, A., Grun, M. K., Mao, T., Israelow, B., Reschke, M., Grundler, J., Akhtar, L., Lee, T., Shin, K., Piotrowski-Daspit, A. S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0603 · Cited by 175
Wang, Y.-S., Kumari, M., Chen, G.-H., Hong, M.-H., Yuan, J. P.-Y., Tsai, J.-L., & Wu, H.-C. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00977-5 · Cited by 173
“These vaccines were each ~ 90% effective in terms of preventing wild-type SARS-CoV-2 infection in fully vaccinated individuals and ~ 80% effective in partially vaccinated adults [74, 161, 216].”
BackgroundInfluentialLoughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173
Pollock, K. M., Cheeseman, H. M., Szubert, A. J., Libri, V., Boffito, M., Owen, D., Bern, H., McFarlane, L. R., O'Hara, J., Lemm, N.-M., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101262 · Cited by 173
Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies
Lopes-Pacheco, M., Silva, P. L., Cruz, F. F., Battaglini, D., Robba, C., Pelosi, P., Morales, M. M., Caruso Neves, C., & Rocco, P. R. M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.593223 · Cited by 170
Tsai, R., Hervey, J., Hoffman, K., Wood, J., Johnson, J., Deighton, D., Clermont, D., Loew, B., & Goldberg, S. L. (2022) · JMIR Public Health and Surveillance · doi:10.2196/29872 · Cited by 170
Current Advances in RNA Therapeutics for Human Diseases
Zogg, H., Singh, R., & Ro, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052736 · Cited by 172
“BNT162b2 IM Immunogenicity and antibody response to SARS-CoV-2 S antigens SARS-CoV-2 S antigens’ expression COVID-19 BioNTech and Pfizer FDA (2020) [31]”
BackgroundInfluentialKremsner, P. G., Ahuad Guerrero, R. A., Arana-Arri, E., Aroca Martinez, G. J., Bonten, M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00677-0 · Cited by 172
Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.001 · Cited by 167
Drug delivery systems for CRISPR-based genome editors
Madigan, V., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 172
“220,221) or its variants 222 .”
MethodInfluentialTurner, P. J., Ansotegui, I. J., Campbell, D. E., Cardona, V., Ebisawa, M., El-Gamal, Y., Fineman, S., Geller, M., Gonzalez-Estrada, A., Greenberger, P. A., et al. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100517 · Cited by 169
Recent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 173
“1%, respectively, demonstrating the high effectiveness of the mRNA vaccine against the novel coronavirus pneumonia [3,4].”
BackgroundEvaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia
Alhazmi, A., Alamer, E., Daws, D., Hakami, M., Darraj, M., Abdelwahab, S., Maghfuri, A., & Algaissi, A. (2021) · Vaccines · doi:10.3390/vaccines9060674 · Cited by 170
“BNT162b2 mRNA vaccine has been developed to stimulate immune response against SARS-CoV-2 using mRNA coding SARS-CoV-2 spike protein [8,9].”
BackgroundMethodResultInfluentialBlood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system
Wang, C., Xue, Y., Markovic, T., Li, H., Wang, S., Zhong, Y., Du, S., Zhang, Y., Hou, X., Yu, Y., et al. (2025) · Nature Materials · doi:10.1038/s41563-024-02114-5 · Cited by 171
Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac262 · Cited by 283
Efficacy of COVID-19 vaccines in immunocompromised patients: A systematic review and meta-analysis
Lee, A. R. Y. B., Wong, S.-Y., Chai, L. Y. A., Lee, S., Lee, M., Muthiah, M. D., Tay, S. H., Teo, C., Tan, B. K. J., Chan, Y., et al. (2021) · medRxiv · doi:10.1101/2021.09.28.21264126 · Cited by 6
“after the first dose and 90% after the second dose for the BioNTech-Pfizer vaccine(4), while”
BackgroundElapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study
Israel, A., Merzon, E., Schäffer, A. A., Shenhar, Y., Green, I., Golan-Cohen, A., Ruppin, E., Magen, E., & Vinker, S. (2021) · BMJ · doi:10.1136/bmj-2021-067873 · Cited by 170
Pimpinelli, F., Marchesi, F., Piaggio, G., Giannarelli, D., Papa, E., Falcucci, P., Pontone, M., Di Martino, S., Laquintana, V., La Malfa, A., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01090-6 · Cited by 169
“Discussion Two mRNA vaccines have been approved by FDA and EMA, having demonstrated to enhance effectively immunogenicity against SARS-CoV-2 in general population [24, 25].”
BackgroundAl‐Metwali, B. Z., Al‐Jumaili, A. A., Al‐Alag, Z. A., & Sorofman, B. (2021) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13581 · Cited by 170
Population antibody responses following COVID-19 vaccination in 212,102 individuals
Ward, H., Whitaker, M., Flower, B., Tang, S. N., Atchison, C., Darzi, A., Donnelly, C. A., Cann, A., Diggle, P. J., Ashby, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28527-x · Cited by 168
COVID-19 Vaccine Acceptance in the Democratic Republic of Congo: A Cross-Sectional Survey
Ditekemena, J. D., Nkamba, D. M., Mutwadi, A., Mavoko, H. M., Siewe Fodjo, J. N., Luhata, C., Obimpeh, M., Van Hees, S., Nachega, J. B., & Colebunders, R. (2021) · Vaccines · doi:10.3390/vaccines9020153 · Cited by 168
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
Levy, I., Wieder-Finesod, A., Litchevsky, V., Biber, A., Indenbaum, V., Olmer, L., Huppert, A., Mor, O., Goldstein, M., Levin, E. G., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.031 · Cited by 173
“The Pfizer-BioNTech BNT162b2 mRNA vaccine has been tested for safety and efficacy in a multinational randomized placebocontrolled trial with more than 40 000 participants [1].”
MethodIncreased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
(2021) · doi:10.21203/rs.3.rs-155394/v1 · Cited by 2,312
Recent Advancement in mRNA Vaccine Development and Applications
Al Fayez, N., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 167
“Two doses of BNT162b2 proved to be 87% effective at preventing hospitalizations, 94% effective at preventing symptomatic COVID-19, and 95% overall effective at preventing COVID-19 [9,94].”
BackgroundDanthu, C., Hantz, S., Dahlem, A., Duval, M., Ba, B., Guibbert, M., El Ouafi, Z., Ponsard, S., Berrahal, I., Achard, J.-M., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021040490 · Cited by 164
Mahil, S. K., Bechman, K., Raharja, A., Domingo-Vila, C., Baudry, D., Brown, M. A., Cope, A. P., Dasandi, T., Graham, C., Lechmere, T., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00212-5 · Cited by 166
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P., Al Kanaani, Z., et al. (2021) · JAMA · doi:10.1001/jama.2021.19623 · Cited by 162
MacIntyre, C. R., Costantino, V., & Trent, M. (2022) · Vaccine · doi:10.1016/j.vaccine.2021.04.042 · Cited by 166
Milošević Đorđević, J., Mari, S., Vdović, M., & Milošević, A. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2021.113930 · Cited by 161
Whitaker, H. J., Tsang, R. S. M., Byford, R., Andrews, N. J., Sherlock, J., Sebastian Pillai, P., Williams, J., Button, E., Campbell, H., Sinnathamby, M., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2021.12.044 · Cited by 165
Szebeni, J., Storm, G., Ljubimova, J. Y., Castells, M., Phillips, E. J., Turjeman, K., Barenholz, Y., Crommelin, D. J. A., & Dobrovolskaia, M. A. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01071-x · Cited by 165
Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients
Li, Y., Ma, M.-L., Lei, Q., Wang, F., Hong, W., Lai, D.-Y., Hou, H., Xu, Z.-W., Zhang, B., Chen, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108915 · Cited by 162
Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination
(2021) · doi:10.1101/2021.03.03.21251066 · Cited by 509
Ghostine, R., Gharamti, M., Hassrouny, S., & Hoteit, I. (2021) · Mathematics · doi:10.3390/math9060636 · Cited by 160
Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm
Wang, W., Feng, S., Ye, Z., Gao, H., Lin, J., & Ouyang, D. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.021 · Cited by 165
Zhang, P., Narayanan, E., Liu, Q., Tsybovsky, Y., Boswell, K., Ding, S., Hu, Z., Follmann, D., Lin, Y., Miao, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01574-5 · Cited by 162
Li, B., Jiang, A. Y., Raji, I., Atyeo, C., Raimondo, T. M., Gordon, A. G. R., Rhym, L. H., Samad, T., MacIsaac, C., Witten, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01082-6 · Cited by 164
“Hence, isocyanoacetates 1, 2 and 3 gave the cyclic imidazoline product, while isocyanides 4, 5 and 6 showed the alpha-amino amide product.”
mRNA cancer vaccines: Advances, trends and challenges
He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J.-Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 165
Català, M., Mercadé-Besora, N., Kolde, R., Trinh, N. T. H., Roel, E., Burn, E., Rathod-Mistry, T., Kostka, K., Man, W. Y., Delmestri, A., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00414-9 · Cited by 162
Nanotechnology-based mRNA vaccines
Chen, S., Huang, X., Xue, Y., Álvarez-Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 165
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
Mok, C. K. P., Cohen, C. A., Cheng, S. M. S., Chen, C., Kwok, K., Yiu, K., Chan, T., Bull, M., Ling, K. C., Dai, Z., et al. (2022) · Respirology · doi:10.1111/resp.14191 · Cited by 162
Rowe, S. M., Zuckerman, J. B., Dorgan, D., Lascano, J., McCoy, K., Jain, M., Schechter, M. S., Lommatzsch, S., Indihar, V., Lechtzin, N., et al. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.04.008 · Cited by 160
Furer, V., Zisman, D., Kibari, A., Rimar, D., Paran, Y., & Elkayam, O. (2021) · Rheumatology · doi:10.1093/rheumatology/keab345 · Cited by 161
“Two mRNA-based vaccines, BNT162b2 and mRNA-1273, have demonstrated a high efficacy rate with an acceptable safety profile(1,2), leading to their expedited authorization by the regulatory authorities.”
BackgroundMoline, H. L., Whitaker, M., Deng, L., Rhodes, J. C., Milucky, J., Pham, H., Patel, K., Anglin, O., Reingold, A., Chai, S. J., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7032e3 · Cited by 161
Matrajt, L., Eaton, J., Leung, T., Dimitrov, D., Schiffer, J. T., Swan, D. A., & Janes, H. (2021) · Nature Communications · doi:10.1038/s41467-021-23761-1 · Cited by 177
“(3) Then we will vaccinate 15% of adults aged 65–75 with one dose, and finally (4) we will vaccinate 10% of those aged 20–50 with a single dose.”
Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease
Balcom, E. F., Nath, A., & Power, C. (2021) · Brain · doi:10.1093/brain/awab302 · Cited by 160
A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection
Humphries, F., Shmuel-Galia, L., Jiang, Z., Wilson, R., Landis, P., Ng, S.-L., Parsi, K. M., Maehr, R., Cruz, J., Morales, A., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi9002 · Cited by 158
Boekel, L., Steenhuis, M., Hooijberg, F., Besten, Y. R., van Kempen, Z. L. E., Kummer, L. Y. L., van Dam, K. P. J., Stalman, E. W., Vogelzang, E. H., Cristianawati, O., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00222-8 · Cited by 160
Evaluation of COVID-19 vaccination strategies with a delayed second dose
Moghadas, S. M., Vilches, T. N., Zhang, K., Nourbakhsh, S., Sah, P., Fitzpatrick, M. C., & Galvani, A. P. (2021) · PLOS Biology · doi:10.1371/journal.pbio.3001211 · Cited by 154
Chen, J., Xu, Y., Zhou, M., Xu, S., Varley, A. J., Golubovic, A., Lu, R. X. Z., Wang, K. C., Yeganeh, M., Vosoughi, D., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2309472120 · Cited by 160
SARS-CoV-2-specific T cells in infection and vaccination
Bertoletti, A., Le Bert, N., Qui, M., & Tan, A. T. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00743-3 · Cited by 159
“The interesting point of this longitudinal study is that the clinical trial of BNT162b2 vaccine efficacy showed that protection from symptomatic disease began approximately 10 days after the first dose [52].”
BackgroundCOVID-19 vaccines and decreased transmission of SARS-CoV-2
Vitiello, A., Ferrara, F., Troiano, V., & La Porta, R. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00847-2 · Cited by 159
BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies
Herzog Tzarfati, K., Gutwein, O., Apel, A., Rahimi‐Levene, N., Sadovnik, M., Harel, L., Benveniste‐Levkovitz, P., Bar Chaim, A., & Koren‐Michowitz, M. (2021) · American Journal of Hematology · doi:10.1002/ajh.26284 · Cited by 159
Heidecker, B., Dagan, N., Balicer, R., Eriksson, U., Rosano, G., Coats, A., Tschöpe, C., Kelle, S., Poland, G. A., Frustaci, A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2669 · Cited by 159
Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
Rzymski, P., Poniedziałek, B., & Fal, A. (2021) · Vaccines · doi:10.3390/vaccines9111286 · Cited by 170
Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung
Popowski, K. D., López de Juan Abad, B., George, A., Silkstone, D., Belcher, E., Chung, J., Ghodsi, A., Lutz, H., Davenport, J., Flanagan, M., et al. (2022) · Extracellular Vesicle · doi:10.1016/j.vesic.2022.100002 · Cited by 158
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
Watanabe, Y., Mendonça, L., Allen, E. R., Howe, A., Lee, M., Allen, J. D., Chawla, H., Pulido, D., Donnellan, F., Davies, H., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00080 · Cited by 155
Maternal vaccination: a review of current evidence and recommendations
Etti, M., Calvert, A., Galiza, E. P., Lim, S., Khalil, A. A., Doaré, K. L., & Heath, P. T. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.10.041 · Cited by 182
“In both circumstances, the initial vaccine safety data in pregnancy were collected from pregnant women who either inadvertently or deliberately received the vaccine in/outside of trials, highlighting the need for a more coordinated approach to facilitate the earlier inclusion of pregnant women in these trials.(12,14)…”
BackgroundSynthesis and Potential Applications of Lipid Nanoparticles in Medicine
Musielak, E., Feliczak-Guzik, A., & Nowak, I. (2022) · Materials · doi:10.3390/ma15020682 · Cited by 159
Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity
Matchett, W. E., Joag, V., Stolley, J. M., Shepherd, F. K., Quarnstrom, C. F., Mickelson, C. K., Wijeyesinghe, S., Soerens, A. G., Becker, S., Thiede, J. M., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100421 · Cited by 156
Short‐term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID ‐19 vaccine
Bookstein-Peretz, S., Regev, N., Novick, L., Nachshol, M., Goffer, E., Ben‐David, A., Asraf, K., Doolman, R., Levin, E. G., Regev‐Yochay, G., et al. (2021) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.23729 · Cited by 178
Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncologic Patients
Özütemiz, C., Krystosek, L. A., Church, A., et al. (2021) · Radiology · doi:10.1148/radiol.2021210275 · Cited by 157
Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy
Witten, J. J., Raji, I. O., Manan, R. S., Beyer, E., Bartlett, S., Tang, Y., Ebadi, M., Lei, J., Nguyen, D., Oladimeji, F. A., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02490-y · Cited by 237
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdiş, C. A., & Novak, N. (2020) · Allergy · doi:10.1111/all.14711 · Cited by 157
Haas, J. W., Bender, F. L., Ballou, S., Kelley, J. M., Wilhelm, M., Miller, F. G., Rief, W., & Kaptchuk, T. J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.43955 · Cited by 202
The basis of a more contagious 501Y.V1 variant of SARS-CoV-2
Liu, H., Zhang, Q., Wei, P., Chen, Z., Aviszus, K., Yang, J., Downing, W., Jiang, C., Liang, B., Reynoso, L., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00496-8 · Cited by 156
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
Bradley, T., Grundberg, E., Selvarangan, R., LeMaster, C., Fraley, E., Banerjee, D., Belden, B., Louiselle, D., Nolte, N., Biswell, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102051 · Cited by 155
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects
Wheeler, S., Shurin, G. V., Yost, M., Anderson, A., Pinto, L., Wells, A. H., & Shurin, M. R. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00341-21 · Cited by 163
“The trial found that two doses of BNT162b2 demonstrated 95% protection against COVID-19 (7).”
BackgroundAntibody titres decline 3-month post-vaccination with BNT162b2
Favresse, J., Bayart, J., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Wieërs, G., Laurent, C., Dogné, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1953403 · Cited by 158
Zhou, P., Song, G., Liu, H., Yuan, M., He, W.-T., Beutler, N., Zhu, X., Tse, L. V., Martinez, D. R., Schäfer, A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.02.005 · Cited by 150
“S (n = 1: CC67), or Moderna mRNA-1273 (n = 5: CC24, CC25, CC26, CC68, and CC84) vaccines (Figures S1A and S1B).(2,70,71) Except for two mAbs that failed to bind stem-helix peptide from human coronavirus HKU1 (HCoV-HKU1), all mAbs bound to stem-helix peptides of endemic b-HCoV (HCoV-HKU1 and HCoV-OC43) but not a-HCoVs…”
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022) · Nature Communications · doi:10.1038/s41467-022-30884-6 · Cited by 143
He, Q., Mao, Q., An, C., Zhang, J., Gao, F., Bian, L., Li, C., Liang, Z., Xu, M., & Wang, J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1902245 · Cited by 158
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19
Lobo, N., Brooks, N. A., Zlotta, A. R., Cirillo, J. D., Boorjian, S. A., Black, P. C., Meeks, J. J., Bivalacqua, T. J., Gontero, P., Steinberg, G. D., et al. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00481-1 · Cited by 178
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.